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Abstract
Introduction Increasing parity and age at first full-term
pregnancy are established risk factors for breast cancer in the
general population. However, their effects among BRCA1 and
BRCA2  mutation carriers is still under debate. We used
retrospective data on BRCA1 and BRCA2 mutation carriers
from the UK to assess the effects of parity-related variables on
breast cancer risk.
Methods The data set included 457 mutation carriers who
developed breast cancer (cases) and 332 healthy mutation
carriers (controls), ascertained through families seen in genetic
clinics. Hazard ratios were estimated by using a weighted cohort
approach.
Results Parous BRCA1 and BRCA2 mutation carriers were at
a significantly lower risk of developing breast cancer (hazard
ratio 0.54, 95% confidence interval 0.37 to 0.81; p = 0.002).
The protective effect was observed only among carriers who
were older than 40 years. Increasing age at first live birth was
associated with an increased breast cancer risk among BRCA2
mutation carriers (p trend = 0.002) but not BRCA1 carriers.
However, the analysis by age at first live birth was based on
small numbers.
Conclusion The results suggest that the relative risks of breast
cancer associated with parity among BRCA1  and  BRCA2
mutation carriers may be similar to those in the general
population and that reproductive history may be used to improve
risk prediction in carriers.
Introduction
Deleterious mutations in the BRCA1 and BRCA2 genes are
associated with high risks of breast and ovarian cancer [1].
However, there is evidence that these risks are modified by
both genetic and environmental factors [1-4]. Breast cancer
risk in the general population is closely related to reproductive
history, and reproductive factors are therefore strong candi-
dates for modifiers of breast cancer risk in BRCA1  and
BRCA2 mutation carriers. In particular, increasing parity has
been shown to be protective for breast cancer in the general
population in many studies [5-7], but its effect among BRCA1
and BRCA2 mutation carriers is still under debate [8-14]. In
this report we have used data from 810 BRCA1 and BRCA2
mutation carriers from the UK to assess the effect of parity on
breast cancer risk.
Materials and methods
Families with breast and/or ovarian cancer have been tested
for BRCA1/2 mutations since 1996 in the overlapping regions
of North-West England and the West Midlands, covering
about 10 million people. Women attending the specialist
genetic clinics in these two regions with a family history of
breast or ovarian cancer have a detailed three-generation fam-
ily tree elicited. If a pathogenic BRCA1/2 mutation is identi-
fied, further attempts are made to ensure that all individuals
relevant to discussions (those who could potentially carry any
predisposing mutation) on risk are represented on the family
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tree. For the purposes of this analysis, pathogenic mutations
include frameshift mutations, pathogenic splice variants, large
rearrangements, or missense mutations classified as patho-
genic by Breast Cancer Information Core [15]. All cases of
breast or abdominal cancers are confirmed by means of hos-
pital or pathology records from the Regional Cancer Regis-
tries (data available from 1960) or from death certification.
Once a family-specific pathogenic BRCA1/2 mutation is iden-
tified, predictive testing is offered to all blood relatives. Where
possible all affected women with breast or ovarian cancer are
tested to establish the true extent of BRCA1/2 involvement in
the family. In many instances this is done by obtaining paraffin-
embedded tumour block material from deceased relatives. In
many large families it is possible to establish 'obligate' gene
carriers by testing for the same mutation in different branches
of the family, thereby establishing that intervening relatives
carry the same mutation.
All female BRCA1/2  mutation carriers identified by the
regional genetics services were eligible for this study; their
details and those of all tested relatives and first-degree
untested female relatives were entered in a Filemaker Pro 5
database. The initial individual in which a mutation was identi-
fied was designated the 'index' case, with all other individuals
being classified as to their position in the pedigree compared
with a proven mutation carrier. Dates of births for the first and
last completed third-trimester pregnancies, before breast can-
cer, or last follow-up were entered in the database for each of
these women. The exception was mothers of a mutation carrier
when it was clear that the mutation was paternally inherited.
This study was approved by the Central Manchester Local
research ethics committee, and participants consented to the
Genetics Register research.
A total of 476 BRCA1 and 334 BRCA2 mutation carriers
were used in a retrospective analysis of parity. Twenty-one
parous carriers with a missing date at first live birth or for
whom the age at first live birth could not be estimated from the
available data were excluded from the analyses. The remaining
individuals were censored (for instance, follow up was com-
pleted) at the age of breast cancer diagnosis (457), the age at
ovarian cancer diagnosis (138), the age at mastectomy (37),
the age at death (31) or the age at interview or last follow-up
(126), whichever occurred first. Only carriers who were cen-
sored at breast cancer diagnosis were assumed to be
affected. Among the 789 BRCA1 and BRCA2 mutation carri-
ers included in the analyses, 647 were tested carriers and 142
were classified as obligate carriers by virtue of their position in
the pedigree. The carriers originated from 392 distinct fami-
lies. In all analyses we considered the number of full-term preg-
nancies occurring before the censoring age.
The effect of parity on breast cancer risk among BRCA1 and
BRCA2 mutation carriers was assessed with the use of time-
dependent Cox regression, and the effects are expressed as
hazard ratios (HRs). According to the sampling design,
affected mutation carriers may be preferentially sampled. In
standard Cox regression the HR is estimated by comparing
the distribution of the risk factor among affected individuals
with the distribution among unaffected individuals at a partic-
ular time point. In the present study design, affected individu-
als are compared with unaffected carriers who were selected
on the basis of their future disease status. However, if a risk
factor was associated with breast cancer, then the risk factor
would be over-represented among these unaffected carriers
(because they would develop breast cancer in the future) and
the HR under standard Cox regression would be biased
towards 1 [16]. To correct for this potential bias we used a
weighted cohort approach to analyse the effect of parity [16].
Under this method, individuals are weighted such that the
observed breast cancer incidence rates in the study sample
are consistent with established estimates of breast cancer risk
among BRCA1 and BRCA2 mutation carriers. It has been
shown that this approach gives estimates that are close to
unbiased [16]. Weights were computed separately for
BRCA1 and BRCA2 mutation carriers by using the breast
cancer incidence rate estimates reported in the meta-analysis
of Antoniou and colleagues [1].
BRCA1  and BRCA2  mutation carriers were considered in
both combined and separate analyses. All analyses were strat-
ified by the year of birth (before 1940, 1940 to 1949, 1950 to
1959, 1960 and later) and adjusted for oophorectomy. The
joint analysis was also stratified by gene. We allowed for the
fact that several individuals may come from the same family by
using robust variance estimation [17,18]. For direct compari-
son we present our results in a similar format to that in the
report of Andrieu and colleagues [19]. Because only age at
first and age at last birth were recorded for carriers with more
than two live births, intermediate births were assumed to occur
at equally spaced intervals. Analyses were performed with
STATA version 9 statistical software (Stata Corporation, Col-
lege Station, TX, USA).
Results
Table 1 shows a summary of the characteristics for the
affected and unaffected carriers used in the analysis. The
mean age at diagnosis for the affected individuals was lower
than the censoring age for the unaffected carriers (43.4 and
47.3 years, respectively). The mean age at censoring was sim-
ilar for BRCA1 and BRCA2 mutation carriers (44.7 and 45.4
years, respectively).
The results of the parity analyses using weighted Cox regres-
sion are shown in Table 2. Parous mutation carriers had a sig-
nificantly lower risk of developing breast cancer (HR = 0.54,
95% confidence interval (CI) 0.37 to 0.81; p = 0.002). Having
at least one live birth was protective in both BRCA1  and
BRCA2 mutation carriers, and the HR did not differ signifi-
cantly by gene, although the effect was statistically significantAvailable online http://breast-cancer-research.com/content/8/6/R72
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only among BRCA1 mutation carriers (p = 0.006). When the
data were analysed by attained age, parity was found to be
protective only among carriers over the age of 40 years (HR =
0.44, 95% CI 0.23 to 0.84; p = 0.013; p = 0.048 for the dif-
ference in HR between 40 years or less and more than 40
years). For mutation carriers under the age of 40 years, the HR
was estimated to be 1.01 (95% CI 0.58 to 1.76).
There was evidence that increasing number of live births was
associated with a decreasing risk of breast cancer in BRCA1
and BRCA2 mutation carriers combined. Each additional live
birth was found to reduce breast cancer risk by 10% (HR =
0.90, 95% CI 0.80 to 1.00; p trend = 0.058). The reduction in
risk with each additional birth was similar in BRCA1  and
BRCA2 mutation carriers. However, two or more births con-
ferred significantly lower breast cancer risk only among
BRCA1 mutation carriers. There was some suggestion that
increasing age at first live birth increased the risk of breast
cancer among mutation carriers, but this was not statistically
significant (for age 30 years or more at first live birth, HR =
1.30, 95% CI 0.74 to 2.29; p  trend = 0.38). The effect
seemed to be stronger in BRCA2 mutation carriers, particu-
larly for age 30 years and over (HR = 4.77, 95% CI 2.08 to
10.94; p trend = 0.002), but the latter estimate was based on
only 32 cases.
Discussion
It is well established that increasing parity and early age at first
birth are associated with a lower risk of developing breast can-
cer in the general population. There is evidence that the pro-
tective effect of parity may be restricted to women who are
older than 40 years old [7,20-22]. Our results suggest that
parity may have a similar effect on breast cancer risk among
BRCA1 and BRCA2 mutation carriers. We found evidence
that parous mutation carriers are associated with a lower risk
of developing breast cancer and that the protective effect may
be limited to carriers above the age of 40 years. This effect
was observed only among BRCA1 mutation carriers, but there
were no statistically significant differences in the estimates
between BRCA1 and BRCA2 mutation carriers. There was no
suggestion that parity might increase the risk of developing
breast cancer in mutation carriers under the age of 40 years.
There was evidence that all levels of parity are associated with
a reduced risk of breast cancer among mutation carriers, but
this was statistically significant only for carriers with two or
more live births. There was also some suggestion of an
increased risk associated with first birth after the age of 30
years, again consistent with the effect seen in the general pop-
ulation. However, this effect seemed to be restricted to
BRCA2 mutation carriers. This difference might suggest dif-
ferences in the development of breast cancer among BRCA1
and BRCA2 mutation carriers. Most breast cancer in BRCA1
mutation carriers arises in so-called 'basal' cells that stain pos-
itive for certain cytokeratins [23]. It might be that such cells are
less responsive to the differentiation induced by pregnancy.
However, it should be noted that the gene-specific effects of
age at first birth were not a specific hypothesis in this study,
and this difference may be attributable to chance.
Several studies, using a variety of designs, have investigated
the effect of parity on breast cancer risk among BRCA1 and
BRCA2 mutation carriers, but the results have not been con-
sistent. Some studies have not found any significant associa-
tion with parity [10,13,14], whereas others have reported that
parity may increase the risk of breast cancer in mutation carri-
ers [9,12]. Among these authors, Jernstrom and colleagues
[12] found an increase in risk of breast cancer among carriers
under the age of 40 years. However, this association was not
Table 1
Summary characteristics for affected and unaffected carriers
Parameter Total Affected Unaffected
BRCA1 BRCA2 BRCA1 BRCA2
Number of carriers, n 789 248 209 218 114
Age at censoring, years (mean ± SD) 45.0 ± 11.3 42.9 ± 9.6 43.9 ± 9.3 46.8 ± 13.0 48.3 ± 13.0
Year of birth, n (%)
Before 1940 247 78 (31.5) 64 (30.6) 78 (35.8) 27 (23.7)
1940 to 1949 185 69 (27.8) 61 (29.2) 40 (18.3) 15 (13.2)
1950 to 1959 169 58 (23.4) 48 (23.0) 34 (15.6) 29 (25.4)
1960 and after 188 43 (17.3) 36 (17.2) 66 (30.3) 43 (37.7)
Censoring age, n (%)
<55 years 670 226 (91.1) 185 (88.5) 172 (78.9) 87 (76.3)
≥55 years 119 22 (8.9) 24 (11.5) 46 (21.1) 27 (23.7)
Oophorectomy before censoring age, n 45 5 7 25 8Breast Cancer Research    Vol 8 No 6    Antoniou et al.
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present in a more recent, larger study by the same group [9],
which is in line with our findings. In this latter report they found
evidence of increasing risk with increasing parity among
BRCA2 mutation carriers and that BRCA1 mutation carriers
with four of more children were at a significantly lower risk of
developing breast cancer than nulliparous carriers [9]. In con-
trast, we found evidence that increasing parity was protective
among both BRCA1 and BRCA2 mutation carriers, and that
BRCA1 mutation carriers with two or more offspring had a sig-
nificantly lower breast cancer risk.
Our results are more in line with a recently published study by
Andrieu and colleagues [19]. The estimates for the effects of
parity from both studies are in the same direction and in some
cases of similar magnitude. Andrieu and colleagues found that
BRCA1 mutation carriers who had their first full-term preg-
nancy after the age of 30 years had a significantly lower risk of
developing breast cancer. We did not find a significant evi-
dence for this in the present study, but the confidence interval
of our estimate includes the estimate of Andrieu and col-
leagues. As did Andrieu and colleagues [19], we found a sig-
nificant association for breast cancer risk and pregnancy at
older ages among BRCA2 mutation carriers. One hundred
and forty-six carriers used in the present analysis were also
used in the analysis by Andrieu and colleagues. We repeated
our analysis by excluding those records. The results were vir-
tually the same as those already presented, with similar con-
clusions (results not shown). The data overlap alone therefore
does not explain the agreement between the two studies. Both
the present analysis and that by Andrieu and colleagues [19]
were performed with a weighted Cox regression approach,
Table 2
Results from weighted Cox regression analysis
Parameter All BRCA1 carriers BRCA2 carriers
UN BC HR 95% CI UN BC HR 95% CI UN BC HR 95% CI
Parity
Nulliparous 37 65 1.00 25 37 1.00 12 28 1.00
Parous 295 392 0.54 0.37–0.81 193 211 0.53 0.34–0.83 102 181 0.58 0.27–1.24
Parity by attained age
≤40 years
Nulliparous 28 44 1.00 21 24 1.00 7 20 1.00
Parousa 76 127 1.01 0.58–1.76 50 76 1.17 0.55–2.52 26 51 0.72 0.42–1.24
>40 years
Nulliparous 9 21 1.00 4 13 1.00 5 8 1.00
Parous 219 265 0.44 0.23–0.84 143 135 0.34 0.16–0.70 76 130 1.21 0.37–3.92
Number of live birthsb
Nulliparous 37 65 1.00 25 37 1.00 12 28 1.00
1 46 57 0.62 0.37–1.02 27 34 0.62 0.34–1.11 19 23 0.58 0.22–1.53
2 109 167 0.57 0.38–0.86 73 80 0.54 0.33–0.87 36 87 0.68 0.31–1.47
3 66 79 0.64 0.34–0.86 42 50 0.56 0.33–0.97 24 29 0.44 0.19–1.04
4+ 56 82 0.55 0.34–0.91 42 44 0.51 0.29–0.89 14 38 0.71 0.27–1.88
Per live birth 0.90 0.80–1.00 0.89 0.78–1.01 0.93 0.75–1.14
Age at first live birth
< 2 0  y e a r s 6 15 5 1 . 0 0 3 83 5 1 . 0 0 2 32 0 1 . 0 0
20–24 years 132 179 1.16 0.76–1.78 85 92 1.08 0.65–1.78 47 87 1.74 0.87–3.49
25–29 years 106 108 1.13 0.72–1.79 73 66 1.08 0.64–1.52 33 42 1.48 0.68–3.22
≥ 30 years 39 50 1.30 0.74–2.29 25 18 0.83 0.42–1.64 14 32 4.77 2.08–10.94
Nulliparous 37 65 2.09 1.26–3.45 25 37 1.96 1.10–3.52 12 28 2.85 1.13–7.15
UN, unaffected carriers; BC, breast cancer; HR, hazard ratio; CI, confidence interval. aAnalyses not adjusted for oophorectomy (all others 
adjusted). Overall analysis stratified by year of birth and gene. bAssuming that births between first and last birth were equally spaced; 25 carriers 
(7 affected, 18 unaffected) with missing age at last birth were assumed to be nulliparous until age at first birth and were then considered as a 
separate category (hazard ratios not shown).Available online http://breast-cancer-research.com/content/8/6/R72
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which may further contribute to the consistency between the
studies.
As described above, our analyses also included obligate carri-
ers. Since many of these obligate carriers are mothers of
known carriers and are more likely to be affected, this may
introduce some bias because they are by definition parous.
We therefore repeated all the above analyses, excluding all
obligate carriers (142 subjects). The estimated HRs were very
similar to those obtained with the full data set (data not
shown). Thus, there was no evidence that the inclusion of obli-
gate carriers biased the results.
A major issue in the analysis of parity in BRCA1 and BRCA2
mutation carriers is that the decision to opt for genetic testing
may itself be related to parity, because parous women may be
more concerned to be tested. If the size of this selection bias
differs between affected and unaffected carriers, this will bias
the estimated risk associated with parity. This is an issue in all
retrospective studies based on families opting for genetic test-
ing, from which most of the relevant data can be obtained. We
have attempted to reduce this possible bias by including infor-
mation on reproductive history on all known carriers, including
those who are obligate carriers or who have died from a rele-
vant cancer. However, the possibility of selection bias cannot
be ruled out. Population-based or prospective studies could
avoid such biases, but the former are difficult to conduct and
the latter will take many years to complete.
Conclusion
Our results indicate that the relative risk of breast cancer asso-
ciated with parity is similar to that in the general population.
However, further larger studies are required to clarify the effect
of age at first live birth on breast cancer risk among mutation
carriers. Because BRCA1 and BRCA2 mutation carriers are
susceptible to a much higher risk of breast cancer than non-
carriers, the corresponding absolute differences in risk
between parous and nulliparous carriers may be substantial.
For illustration purposes consider an unaffected BRCA1
mutation carrier who is 40 years old. On the basis of the
BRCA1 breast cancer incidence rates estimated by Antoniou
and colleagues [1], the risk of developing breast cancer by the
age of 70 years is 60%. Assuming that the estimated HR of
0.54 associated with parity applies to BRCA1 mutation carri-
ers and using the same method as described by Mitchell and
colleagues [24], the breast risk by 70 years of age for this
mutation carrier is estimated to be 40% if she is parous and
61% if she is nulliparous. Thus, risk estimates used in genetic
counselling could be improved by incorporating reproductive
history, in a similar manner to that recently demonstrated for
mammographic density [24]. However, given the
inconsistencies between studies and the uncertainties in the
age-specific risks, further large and preferably prospective
studies will be required to provide more reliable absolute risk
estimates.
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